Regulatory Show all
April 24 | 2019

2cureX beslutar om företrädesemission inför marknadslansering av IndiTreat®

Read more
April 24 | 2019

2cureX decides on rights issue prior to market launch of IndiTreat®

Read more
April 4 | 2019

2cureX announces commercial collaboration with Gibson Oncology, USA

Read more
April 4 | 2019

2cureX offentliggör kommersiellt samarbete med Gibson Oncology, USA

Read more
April 2 | 2019

Kommuniké från extra bolagsstämma i 2cureX AB (publ)

Read more
April 2 | 2019

Communique from extraordinary general meeting of 2cureX AB (publ)

Read more
March 28 | 2019

2cureX erhåller Notice of Allowance från det amerikanska patentverket

Read more
March 28 | 2019

2cureX receives Notice of Allowance from the United States Patent Office

Read more
March 14 | 2019

Kallelse till extra bolagsstämma i 2cureX AB (publ)

Read more
March 14 | 2019

Notice of extraordinary general meeting in 2cureX AB (publ)

Read more
March 12 | 2019

2cureX utvidgar verksamheten till förebyggande cancermedicin

Read more
March 12 | 2019

2cureX expands its activities to preventive cancer medicine

Read more
March 1 | 2019

2cureX offentliggör bokslutskommuniké för räkenskapsåret 2018

Read more
March 1 | 2019

2cureX publishes year-end report for the fiscal year 2018

Read more
February 20 | 2019

Correction – Lack of reference to MAR – 2cureX reports positive results from an ongoing clinical trial in heavily pre-treated colorectal cancer patients

Read more
February 20 | 2019

Correction – Lack of reference to MAR – 2cureX meddelar positiva resultat från pågående klinisk studie med kraftigt förbehandlade kolorektalcancerpatienter

Read more
February 20 | 2019

2cureX reports positive results from an ongoing clinical trial in heavily pre-treated colorectal cancer patients

Read more
February 20 | 2019

2cureX meddelar positiva resultat från pågående klinisk studie med kraftigt förbehandlade kolorektalcancerpatienter

Read more